G), Acorda Therapeutics Inc. (ACOR), Agios Pharmaceuticals (AGIO), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Amgen Inc (AMGN), Biogen Idec (BIIB), Celgene (CELG), ChemoCentryx, Inc. (CCXI), Dynavax (DVAX), Enanta Pharmaceuticals (ENTA), Gilead Sciences (GILD), Idenix Pharmaceuticals (I

. located at the end of this report. EFTA00598607 Morgan Stanley MORGAN STANLEY RESEARCH July 23. 2014 Brogan Idec Inc. Risk-Reward Snapshot: Biogen Idec (BIIB, OW, PT $395) Pipeline. Tecfidera and Hemophilia Drive Risk-Reward $50200 (.651.4) 339300(.30W • 200 100 oisaissassisLiamirisaiiiissi Jt

ember 2003, p. 22. 12 Mark Skaletsky (CEO of Trine Pharmaceuticals) was a serial entrepreneur with experience in several biotech companies, notably Biogen Idec, Enzytech, and CelTex. 13 Jim Tananbaum (managing director, Prospect Venture Partners), who held M.D. and MBA degrees from Harvard, was a cofounder

698,200 1,578,640 520,520 Apple Inc =53,820 shares were moved to margin account) 9/5/14 16,914,000 2,071,494 Bank of New =ork Mellon 873,594 Biogen Idec =nc 2/14/12 Facebook =nc 5/17/12 150,000 14,842,506 18,195,000 6/25/14 250,000 9,076,406 10,850,000 9,950,000 2,095 17,500 General =lect

and SpineWave. Ron was previously on the boards of Cerexa (NLV-I company acquired by Forest Laboratories), Stromedix, Inc. (NLV-I company acquired by Biogen Idec), Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica, Inc.), Phase Forward (NASDAQ: PFWD, acquired by Oracle), and Pathology Partners (acqui